Stroehmann Diane 4
4 · Sienna Biopharmaceuticals, Inc. · Filed Aug 1, 2017
Insider Transaction Report
Form 4
Stroehmann Diane
See Remarks
Transactions
- Purchase
Common Stock
2017-08-01$15.00/sh+7,000$105,000→ 124,724 total - Conversion
Series A-3 Preferred Stock
2017-08-01−28,153→ 0 total→ Common Stock (28,153 underlying) - Conversion
Common Stock
2017-08-01+28,153→ 117,724 total
Footnotes (3)
- [F1]The shares of the Issuer's Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
- [F2]The Reporting Person purchased the shares of the Issuer's common stock in connection with the Issuer's initial public offering at the offering price of $15.00 per share.
- [F3]The expiration date is not relevant to the conversion of these securities.